CATUG is steadily advancing its international presence. Recently, we participated in two major global biopharma events, deepening our focus on RNA and advanced therapies while expanding international collaborations.
 

JPM: Showcasing China’s Strength

At the 44th J.P. Morgan Healthcare Conference (JPM), CATUG co-founder and CEO Dr. Wang Xiao joined the Dark Horse Consulting Group’s “Advanced Therapies Landscape Investment Forum.” During the “The China Thing is Real” roundtable, Dr. Wang and other leading experts analyzed the competitiveness of Chinese companies in advanced therapies, their capital attractiveness, and cross-border collaboration opportunities. CATUG demonstrated its technical expertise and compliance framework, highlighting the long-term value of Chinese CDMOs in global nucleic acid drug development.
 

Berlin: On the Frontline of Advanced Therapies in Europe

CATUG’s international team attended the 5th mRNA-Based Therapeutics Summit Europe in Berlin. The summit gathered industry leaders like BioNTech, AstraZeneca, and Roche, as well as innovative companies such as Ethris, Divincell, and CybernaX. Discussions focused on the transition of mRNA from vaccines to therapeutic platforms, emphasizing in vivo precision delivery and targeting hard-to-reach tissues for oncology, rare diseases, regenerative medicine, cardiovascular, and autoimmune applications.
 

Key Insights:
 

1. Therapeutic RNA Matures Across Indications – mRNA is expanding beyond vaccines into multiple therapeutic areas. circRNA and saRNA offer longer expression, lower doses, and better immune profiles, widening treatment windows.
    
2. Advanced In Vivo Delivery Unlocks Hard-to-Reach Tissues – Non-liver-targeting lipid/polymer systems, ligand-directed nanoparticles, and inhaled/local delivery enable efficient and safe expression in lungs, musculoskeletal tissues, and eyes, enhancing chronic disease management and regenerative therapy.
    
3. Regulatory Sandboxes and Platform Approaches Accelerate Clinical Translation – Moderna and BioNTech shared insights on regulatory sandboxes and platform strategies to de-risk and speed up mRNA therapy development. EMA/FDA/MHRA frameworks are becoming clearer, supporting rapid advancement of candidates.
    

CATUG’s full-chain CRDMO platform for DNA-RNA-tLNP supports therapeutic in vivo applications, mRNA, saRNA, circRNA process development, delivery optimization, and GMP manufacturing, helping global clients advance from sequence to clinical supply.
 

By participating in these two events, CATUG demonstrates that leveraging Chinese innovation strengths and focusing on nucleic acid therapies enables sustainable international growth. We will continue to provide multi-modal services to meet global innovation needs and co-create the next era of RNA therapeutics.